Macular disease

A biopharmaceutical company that is developing cheaper anti-VEGF treatments for Australia and other markets has launched a global clinical trial...

Melbourne biopharmaceutical company Opthea has announced its inclusion on the ASX 300, just days after its lead drug candidate met...

A biopharmaceutical company that is developing cheaper anti-VEGF treatments for major global markets, including Australia, has reported positive results from...

Macular Disease Foundation Australia (MDFA) has launched a series of community service announcements featuring national icon Ms Ita Buttrose in...

A safety review into Novartis’ new anti-VEGF drug Beovu has revealed that reported adverse events are consistent with the approved...

Results are imminent in biopharmaceutical company Opthea’s latest clinical trial evaluating the safety and efficacy of its lead drug candidate...

Novartis is working to ensure its newly-approved drug Beovu is accessible via the Pharmaceutical Benefits Scheme (PBS) at the earliest...

A new approach that uses an algorithm to analyse retinal images could help practitioners select the best treatment for patients...

European drug regulators have followed in the footsteps of their Australian and US counterparts, following the approval of Novartis’ new...

The UK’s national health provider has started treating patients with Leber's Congenital Amaurosis (LCA) with a new sight-restoring gene therapy....